» Articles » PMID: 17172671

Long-term Gene Expression in Dividing and Nondividing Cells Using SV40-derived Vectors

Overview
Journal Mol Biotechnol
Publisher Springer
Date 2006 Dec 19
PMID 17172671
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Among the goals of gene therapy is long-term expression of delivered transgenes. Recombinant Tagdeleted SV40 vectors (rSV40s) are especially well suited for this purpose. rSV40s deliver transgene expression that endures for extended periods of time in tissue culture and in vivo, in both dividing and nondividing cells. These vectors are particularly effective in transducing some cell types that have been almost unapproachable using other gene delivery systems, such as quiescent hematopoietic progenitor cells and their differentiated derivatives. Other cellular targets include neurons, brain microglia, hepatocytes, dendritic cells, vascular endothelium, and others. Because rSV40s do not elicit neutralizing antibodies they are useful for in vivo gene delivery in settings where more than one administration may be desirable. The key characteristics of these vectors include their high production titers and therefore suitability for large cell pools, effectiveness in delivering intracellular proteins, and untranslated RNAs, maintenance of transgene expression at constant levels for extended times, suitability for constitutive or conditional promoters and for combinatorial gene delivery and ability to integrate into genomes of both dividing and nondividing cells.

Citing Articles

Current approaches to enhance CNS delivery of drugs across the brain barriers.

Lu C, Zhao Y, Wong H, Cai J, Peng L, Tian X Int J Nanomedicine. 2014; 9:2241-57.

PMID: 24872687 PMC: 4026551. DOI: 10.2147/IJN.S61288.


Pseudovirions as vehicles for the delivery of siRNA.

Lund P, Hunt R, Gottesman M, Kimchi-Sarfaty C Pharm Res. 2009; 27(3):400-20.

PMID: 19998056 PMC: 2831147. DOI: 10.1007/s11095-009-0012-2.


Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.

Kumar A, Singh T, Singh S, Prakash S Biologics. 2009; 3:245-56.

PMID: 19707413 PMC: 2726077.

References
1.
Amalfitano A, Parks R . Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther. 2002; 2(2):111-33. DOI: 10.2174/1566523024605618. View

2.
Wang L, Kaneko S, Honda M, Kobayashi K . Approach to establishing a liver targeting gene therapeutic vector using naturally occurring defective hepatitis B viruses devoid of immunogenic T cell epitope. Virus Res. 2002; 85(2):187-97. DOI: 10.1016/s0168-1702(02)00043-6. View

3.
Westaway E, Mackenzie J, Khromykh A . Kunjin RNA replication and applications of Kunjin replicons. Adv Virus Res. 2003; 59:99-140. DOI: 10.1016/s0065-3527(03)59004-2. View

4.
DeCaprio J, Ludlow J, Figge J, Shew J, Huang C, Lee W . SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell. 1988; 54(2):275-83. DOI: 10.1016/0092-8674(88)90559-4. View

5.
Strayer D, Pomerantz R, Yu M, Rosenzweig M, Bouhamdan M, Yurasov S . Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors. Gene Ther. 2000; 7(10):886-95. DOI: 10.1038/sj.gt.3301159. View